Medicare Enrolled

Dr. Manjeet Chawla, MD

Hematology & Oncology · Chicago, IL
Practice pattern: Clinical Cardiology — Primarily office-based clinical cardiology
Low-engagement
850 W IRVING PARK RD, Chicago, IL 60613
7739756749
In practice since 2006 (19 years)
NPI: 1902910425 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Chawla from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Chawla? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Chawla

Dr. Manjeet Chawla is a hematology & oncology specialist in Chicago, IL, with 19 years of NPI registration. Based on federal Medicare data, Dr. Chawla performed 3,433 Medicare services across 518 unique beneficiaries.

Between the years covered by Open Payments, Dr. Chawla received a total of $18,105 from 62 pharmaceutical and/or device companies across 902 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Chawla is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice ▲ Top 35% volume in IL $18,105 industry payments

Medicare Practice Summary

Medicare Utilization ↗
3,433
Medicare services
Top 35% in IL for hematology & oncology
518
Unique beneficiaries
$80
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~181 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
2,869 $81 $150
Hospital follow-up visit, moderate complexity
Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service.
357 $66 $150
Initial hospital admission, moderate complexity
Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter.
98 $109 $250
Hospital discharge day management, 30 minutes or less
This service covers the final day of hospital care when the patient is being discharged. It includes coordination of care and instructions for the patient within a time frame of 30 minutes or less.
67 $67 $200
New patient office visit (45-59 min)
An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter.
42 $108 $200
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$18,105
Total received (2018-2024)
Avg $2,586/year across 7 years
Top 22% in IL for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
62
Companies
902
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$16,989 (93.8%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$1,116 (6.2%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$2,933
2023
$1,787
2022
$1,528
2021
$1,262
2020
$1,631
2019
$4,692
2018
$4,273

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
GlaxoSmithKline, LLC.
$406
E.R. Squibb & Sons, L.L.C.
$324
PFIZER INC.
$322
Janssen Biotech, Inc.
$305
Novartis Pharmaceuticals Corporation
$208
Lilly USA, LLC
$190
Gilead Sciences, Inc.
$149
Celgene Corporation
$133
Incyte Corporation
$121
Daiichi Sankyo Inc.
$108
Astellas Pharma US Inc
$98
AstraZeneca Pharmaceuticals LP
$76
Merck Sharp & Dohme LLC
$66
GENZYME CORPORATION
$62
Eisai Inc.
$57
Boehringer Ingelheim Pharmaceuticals, Inc.
$54
Alexion Pharmaceuticals, Inc.
$53
ABBVIE INC.
$45
Adaptive Biotechnologies Corporation
$44
Tempus AI, Inc
$39
TerSera Therapeutics LLC
$34
BeiGene USA, Inc.
$25
Mirati Therapeutics, Inc.
$14
Top 3 companies account for 35.9% of 2024 payments
All-time payments by company (2018-2024) ›
Genentech USA, Inc.
$2,181
Amgen Inc.
$1,858
Janssen Biotech, Inc.
$1,486
Novartis Pharmaceuticals Corporation
$1,453
E.R. Squibb & Sons, L.L.C.
$1,083
Merck Sharp & Dohme Corporation
$1,041
PFIZER INC.
$1,011
Celgene Corporation
$879
Lilly USA, LLC
$699
AstraZeneca Pharmaceuticals LP
$629
GENZYME CORPORATION
$541
GlaxoSmithKline, LLC.
$507
Seagen Inc.
$462
Gilead Sciences, Inc.
$351
Clovis Oncology, Inc.
$307
Incyte Corporation
$255
Novocure GmbH
$250
Janssen Pharmaceuticals, Inc
$183
Pharmacyclics LLC, An AbbVie Company
$177
Rigel Pharmaceuticals, Inc.
$176
Eisai Inc.
$168
Astellas Pharma US Inc
$158
BeiGene USA, Inc.
$143
Mirati Therapeutics, Inc.
$137
Exelixis Inc.
$124
Daiichi Sankyo Inc.
$122
Bayer HealthCare Pharmaceuticals Inc.
$121
TerSera Therapeutics LLC
$116
Dova Pharmaceuticals
$109
Boehringer Ingelheim Pharmaceuticals, Inc.
$109
Merck Sharp & Dohme LLC
$106
AbbVie, Inc.
$91
MEDIVATION FIELD SOLUTIONS LLC
$81
Teva Pharmaceuticals USA, Inc.
$73
Alexion Pharmaceuticals, Inc.
$70
TESARO, Inc.
$69
JAZZ PHARMACEUTICALS INC.
$64
Pharmacyclics LLC, an AbbVie Company
$62
Helsinn Therapeutics (U.S.), Inc.
$54
PORTOLA PHARMACEUTICALS, LLC
$49
ABBVIE INC.
$45
Adaptive Biotechnologies Corporation
$44
G1 Therapeutics, Inc.
$42
Tempus AI, Inc
$39
AMAG Pharmaceuticals, Inc.
$35
Regeneron Healthcare Solutions, Inc.
$31
Global Blood Therapeutics, Inc.
$28
ADC Therapeutics America, Inc.
$28
Deciphera Pharmaceuticals Inc.
$23
TOLMAR Pharmaceuticals, Inc.
$21
EMD Serono, Inc.
$20
PUMA BIOTECHNOLOGY, INC.
$20
Seattle Genetics, Inc.
$19
Myriad Genetic Laboratories, Inc.
$19
Jazz Pharmaceuticals Inc.
$19
EISAI INC.
$18
PORTOLA PHARMACEUTICALS, INC.
$18
Takeda Pharmaceuticals U.S.A., Inc.
$18
SOBI, INC
$18
SANOFI-AVENTIS U.S. LLC
$17
AbbVie Inc.
$15
Janssen Scientific Affairs, LLC
$14
Top 3 companies account for 30.5% of all-time payments
Associated products mentioned in payments ›
ABECMA · ADAKVEO · ADCETRIS · AFINITOR · AKYNZEO · ALIMTA · ANDEXXA · Abraxane · Alecensa · Aliqopa · Aranesp · Avastin · BENDEKA · BEXSERO · BOSULIF · BRUKINSA · Balversa · Blincyto · CABLIVI · CALQUENCE · CHANTIX · COSELA · CYRAMZA · Cabometyx · DARZALEX · Doptelet · ELIGARD · ELIQUIS · ELITEK · ELREXFIO · EMPLICITI · ENHERTU · ENJAYMO · EPKINLY · ERBITUX · ERLEADA · EVENITY · Enhertu · Erleada · FASENRA · FERAHEME · Fabhalta · GAUCHER-DISEASE · GAZYVA · GILOTRIF · IBRANCE · IMBRUVICA · IMFINZI · INLYTA · Idhifa · Imbruvica · JADENU · JAKAFI · JEMPERLI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kadcyla · Kyprolis · LENVIMA · LIBTAYO · LUMAKRAS · LUPRON DEPOT · LUTATHERA · LYNPARZA · Lenvima · Lupron · Lupron Depot · MEKINIST · MONJUVI · MVASI · NERLYNX · Neulasta · Nplate · OJJAARA · ONUREG · OPDIVO · OPDUALAG · OXBRYTA · PADCEV · PIQRAY · PREVNAR 20 · PROMACTA · Padcev · Perjeta · Pomalyst · Prolia · QINLOCK · QUZYTTIR · REBLOZYL · RYDAPT · Revlimid · Rubraca · SARCLISA · SCEMBLIX · SHINGRIX · SUTENT · Stivarga · TAGRISSO · TASIGNA · TECENTRIQ · TECVAYLI · TUKYSA · Tavalisse · Trodelvy · ULTOMIRIS · VARUBI · VENCLEXTA · VERZENIO · VOTRIENT · VYXEOS · Vectibix · Venclexta · Vitrakvi · XALKORI · XARELTO · XGEVA · XTANDI · Xermelo · Xofigo · Xtandi · YONDELIS · ZEJULA · ZEPOSIA · ZEPZELCA · ZYTIGA · clonoSEQ · myRisk
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (94%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Looking for a hematology & oncology specialist in Chicago?
Compare hematology & oncology specialists in the Chicago area by procedure volume, costs, and industry payment transparency.
Browse hematology & oncology specialists nearby

Geographic Context

Hematology & oncology specialists within 10 mi
320
Per 100K population
6.2
County median income
$81,797
Nearest hospital
THOREK MEMORIAL HOSPITAL
0.0 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Chawla is a clinical cardiology specialist, with moderate Medicare volume, with low-engagement industry engagement, with 19 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Chawla experienced with office visit, established patient (30-39 min)?
Based on Medicare claims data, Dr. Chawla performed 2,869 office visit, established patient (30-39 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Chawla receive payments from pharmaceutical companies?
Yes. Dr. Chawla received a total of $18,105 from 62 companies across 902 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Chawla's costs compare to other hematology & oncology specialists in Chicago?
Dr. Chawla's average Medicare payment per service is $80. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Chawla) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →